| Agile Therapeutics is a women's healthcare company. Co.'s primary product candidate, Twirla, also known as AG200-15, is a once-weekly prescription combination hormonal contraceptive patch that is at the end of clinical development. Twirla is a combined hormonal contraceptives patch that contains the active ingredients ethinyl estradiol, which is a synthetic estrogen, and levonorgestrel, which is a type of progestin, a synthetic steroid hormone. Co.'s pipeline consists of two classes of product candidates: Twirla line extensions and other transdermal contraceptive product candidates, including AG200-ER, AG200-SP, AG200-ER, and AG890. We show 29 historical shares outstanding datapoints in our coverage of AGRX's shares outstanding history.|
Understanding the changing numbers of AGRX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AGRX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AGRX by allowing them to research AGRX shares outstanding history
as well as any other stock in our coverage universe.